m6A modification: recent advances, anticancer targeted drug discovery and beyond
m6A modification: recent advances, anticancer targeted drug discovery and beyond
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-related approaches and modern drug discovery platforms have been used in an attempt to develop m6A-ta...
Alternative Titles
Full title
m6A modification: recent advances, anticancer targeted drug discovery and beyond
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_55150f2e80be4a06a51bd1c03eeac7e1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_55150f2e80be4a06a51bd1c03eeac7e1
Other Identifiers
ISSN
1476-4598
E-ISSN
1476-4598
DOI
10.1186/s12943-022-01510-2
